Filing Flows › Novavax (NVAX) › Product sales revenue
Novavax (NVAX) Product sales revenue by quarter
Novavax's Product sales revenue was $25.7M in Q3 2026 (third quarter 2026), +36% from Q2 2026. Over the last 4 quarters it ranged from $10.7M (Q2 2025) to $25.7M (Q3 2026).
| Quarter | Product sales revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $25.7M | +36% | +91% |
| Q2 2026 | $18.9M | +40% | +76% |
| Q3 2025 | $13.4M | +25% | — |
| Q2 2025 | $10.7M | — | — |
Q3 2026 at a glance
Novavax, Q3 2026: revenue $68.3M (-3% year over year), operating margin -45.8%, net loss $31.4M, operating cash flow −$94.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Novavax's Product sales revenue?
Novavax's Product sales revenue was $25.7M in Q3 2026 (third quarter 2026), +36% from Q2 2026.
How has Novavax's Product sales revenue changed?
Over the last 4 quarters it ranged from $10.7M (Q2 2025) to $25.7M (Q3 2026).